Leerink Partnrs Issues Optimistic Estimate for IPSC Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC) – Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for Century Therapeutics in a report issued on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch now expects that the company will post earnings of ($0.09) per share for the year, up from their previous estimate of ($1.75). The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.63) per share. Leerink Partnrs also issued estimates for Century Therapeutics’ Q4 2024 earnings at $0.93 EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.62) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at ($1.54) EPS and FY2028 earnings at ($1.32) EPS.

Several other analysts have also recently issued reports on IPSC. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Piper Sandler dropped their price target on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research report on Monday, December 30th. Chardan Capital dropped their price target on Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Finally, Guggenheim reiterated a “buy” rating on shares of Century Therapeutics in a research report on Wednesday, January 22nd. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Century Therapeutics has a consensus rating of “Buy” and a consensus price target of $10.00.

Century Therapeutics Stock Performance

NASDAQ:IPSC opened at $0.77 on Monday. Century Therapeutics has a one year low of $0.68 and a one year high of $5.51. The business’s 50-day simple moving average is $0.95 and its 200 day simple moving average is $1.33. The stock has a market cap of $65.32 million, a price-to-earnings ratio of -0.42 and a beta of 1.73.

Institutional Trading of Century Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in shares of Century Therapeutics during the third quarter worth $27,000. Marshall Wace LLP acquired a new position in Century Therapeutics during the fourth quarter worth $36,000. Jane Street Group LLC increased its position in Century Therapeutics by 166.2% during the fourth quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock worth $49,000 after buying an additional 29,992 shares during the last quarter. Two Sigma Advisers LP acquired a new position in Century Therapeutics during the fourth quarter worth $52,000. Finally, Sei Investments Co. acquired a new position in Century Therapeutics during the fourth quarter worth $53,000. 50.20% of the stock is currently owned by hedge funds and other institutional investors.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.